藥明康德(02359.HK)擬2000萬美元認購罕見病藥物創新公司北海康成股份
格隆匯2月17日丨藥明康德(02359.HK)公佈，2020年2月15日，公司全資子企業WuXi Pharma Tech Healthcare Fund IL.P.（藥明基金一期）、General Atlantic Singapore CP Pte.Ltd.等8名投資人與北海康成及其他相關方簽署優先股認購協議，其中藥明基金一期擬認購北海康成新發行的169萬股優先股股份，認購金額為2000萬美元；同時，北海康成還將向藥明基金一期發行一項未來可認購北海康成股份的認股權證，藥明基金一期有權在最高1000萬美元的價款範圍內認購北海康成優先股股份。
本輪投資完成，藥明康德持有北海康成股份13.11%（全面攤薄和轉換基礎上，下同），其中通過其全資子公司WuXi App Tec (Hong Kong) Limited持有北海康成股份5.61%，通過藥明基金一期持有北海康成股份7.50%。
北海康成及其子公司最早成立於2012年，是專注於首創罕見病藥物的創新平台型醫藥科技公司，擁有多個罕見病產品管線，有兩款腫瘤產品康普舒?和奈拉替尼已分別在中國大陸和香港地區上市，另有治療亨特綜合徵的Hunterase產品，正在新藥報批階段。本輪募集資金主要用於加速、擴展北海康成原研和引進的罕見病產品管線，進一步擴建商業運營平台和能力，並增加營運資金。
公司稱，北海康成專注於首創罕見病藥物的研發，具備多個罕見病藥物管線。藥明康德為全球生物醫藥行業提供全方位、一體化的新藥研發和生產服務，並最終致力於為患者謀福利。公司認為相較常見疾病領域，中國在罕見病領域有着更為巨大的未滿足患者需求。公司認可北海康成在國內罕見病領域的龍頭醫藥企業地位，投資北海康成是公司在中國的罕見病市場的重要投資舉措。通過本次交易，公司將進一步完善在罕見病領域的生態圈佈局，間接促進罕見病領域的新藥研發，令病患早日獲益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
